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Orchestrated by WHO, across all four countries this rare attempt at screening and brief intervention for problems arising from illegal drug
use identified at front-line health care centres found modest reductions in use/risks, but there was a puzzling opposition between
particularly positive results from Australia and seemingly negative ones from the USA.
Summary Results of the featured study are also available in a research report previously analysed by Findings. Both this and the featured
journal article are drawn on in the following account.
There is good evidence that brief interventions (usually one or two face-to-face counselling sessions) can reduce tobacco and alcohol use
identified by screening tests in primary health care settings, particularly when they capitalise on the results of the test. However, there is
only suggestive evidence of similar effects in respect of illicit drug use, only recently has a culturally neutral screening questionnaire for all
psychoactive substances, including illicit drugs, been available for use in primary care, and most studies were conducted in the USA, UK or
Australia, limiting the international generalisability of the findings.
To address these gaps the World Health Organization (WHO) developed the Alcohol, Smoking and Substance Involvement Screening Test
(ASSIST). Through a series of interview questions it screens for problem or risky use of tobacco, alcohol, cannabis, cocaine, amphetamine-
type stimulants, sedatives, hallucinogens, inhalants, opioids like heroin, and "other drugs". It first asks whether the patient has ever used
these substances, then for those they have, how often in the past three months. Further questions in relation to each used substance ask
about adverse consequences, urges to use, whether the individual has tried but failed to cut down, and whether others have shown concern
over their substance use. Finally the patient is asked if they have injected drugs, if so when, and if recently, how often.
A risk score is calculated for each substance and categorised as low, moderate (harmful but not dependent use) or high (actually or probably
dependent), in turn indicating whether no intervention is needed, a brief intervention to encourage the patient to cut back, or a brief
intervention encouraging them to seek further and/or specialised treatment. ASSIST was primarily intended to identify patients at moderate
risk who may otherwise go undetected and deteriorate.
To test this strategy, in 2003 to 2006, 845 potentially suitable patients were assessed by researchers and/or clinicians at health centres and
other front-line in Australia, India, the United States and Brazil. After completing the ASSIST interview, 731 adults were
found to meet the study's criteria and agreed to join the study; another 51 refused. To join they had to have scored as at moderate risk due
to their use of either cannabis, cocaine, amphetamine-type stimulants, or opioids, but not at from any substance except tobacco.
Two thirds of study participants were men and 72% were employed. They averaged about 31 years of age.
Following assessment patients were randomly allocated to wait for three months before intervention (the group), or to participate
(they all did) in a single brief advice session offered by the same clinician/researcher who had conducted the assessment, focused on the
drug which posed the greatest risk to the patient and/or over which they were most concerned. In a motivational interviewing style, during
this session patients were offered written feedback on their ASSIST scores and the implications (eg, health risks) were explored. They left
with a self-help guide on reducing substance use. On average ASSIST screening took eight minutes and the brief intervention 14 minutes.
86% of the patients were followed up about three months later when the ASSIST test was re-applied. At issue was whether the risk scores
of those who participated in the brief intervention three months before had decreased relative to the control group. How they might have
scored at the follow-up was estimated for the patients who could not be re-assessed.
Main findings
In general across all countries and in each separately, the brief intervention resulted in greater risk reduction, particularly in respect of the
substance on which the intervention had focused.
Total ASSIST risk scores for substances other than alcohol and tobacco fell for both sets of patients, but significantly more so for patients
who had been allocated to the brief intervention. Their scores fell from an average 36 to just under 30, while those of the control group fell
from 36 to 32. In % terms this meant a fall of 18% compared to 11%. This global picture was replicated in each of the countries (most
sharply in Australia) except the USA, where control patients actually reduced their risk more than brief intervention patients, though not to a
statistically significant degree. Patients who scored in the upper half of the moderate risk range reacted about as well to the intervention as
those who scored lower; when the sample was divided in this way, neither intervention effect was statistically significant, though both
neared this criterion.
For just over half the patients their main problem substance was cannabis, and this was the focus of the brief intervention for those
allocated to this procedure. Among these patients, risk reduction in relation to the targeted drug (cannabis) was significantly greater among
patients allocated to the brief intervention. In each country too risk reduction was greater among intervention patients, except again for the
USA, where the order was reversed. Only the results for Brazil and India were statistically significant. For cannabis, only patients at the
higher end of the moderate risk spectrum further reduced their ASSIST scores following intervention.
Across all countries, patients whose primary problem substance was a stimulant (cocaine or amphetamine-type drugs) also reduced their risk
related to these substances more if they had been through the brief intervention. None were recruited in India and the country-specific
statistically significant results were from Brazil and Australia. In respect of these drugs, only patients at the lower end of the moderate risk
spectrum further reduced their ASSIST scores following intervention.
Only in India were there appreciable patients whose main problem substances were opioids. Opioid-related risk reduction was significantly
greater among brief intervention patients than among control patients.
Finally the analysts explored whether there was any evidence that while on average patients reduced their cannabis use in response to the
cannabis-specific brief intervention, they 'compensated' by increasing use of other substances. No statistically significant effects on other
substances were found, and there was actually some reduction in risk related to drinking. Similarly, when the intervention targeted
substances other than cannabis, cannabis use was unaffected.





This study has shown that a brief intervention lasting on average a quarter of an hour and linked to the results of the ASSIST screening test
reduced illicit substance use and associated risk significantly among non-dependent patients identified across a range countries in different
types of front-line health care settings. Risk related to the target drug was reduced without patients 'compensating' by increasing their risky
use of other substances. Except for the USA, the pattern of extra risk reduction after brief intervention was maintained in each of the four
countries. It was also apparent in patients with both a moderately high and a moderately low risk.
In both developing and developed countries, there is a compelling need for a comprehensive approach capable of addressing use of a range
of illicit drugs and of tobacco and alcohol in primary care settings. The findings from this project indicate that the ASSIST screening test and
linked brief intervention can at least partly meet this need, promising to help reduce the burden of disease associated with substance use
and substance use disorders.
Why results differed in the USA is unclear. Possibly the relatively lengthy (10–15 minutes) interview required to establish the patient's consent to join the study
'overwhelmed' the intervention. Possibly too the patients, around 30% of whom had been treated for drug or alcohol problems, were less responsive to a brief
intervention. The authors also point out that screening and intervention was generally conducted by specially trained clinical research staff rather than the centres'
usual staff, and that these same staff also generally conducted initial and follow-up assessments, raising the possibility of bias.
 The puzzling divide between the prominence of research on brief interventions for drinkers, and the lack of similar investigations
among users of other drugs, makes this rare large-scale study particularly welcome. Especially in the Australian (so perhaps too in the UK)
context, it holds out the prospect that this divide is not due to differing efficacy, but a prospect clouded by questions over real-world
applicability and impacts on health.
Though the study recorded statistically significant reductions in drug use severity after research procedures and screening, and significant
extra reductions from the intervention, questions have been raised about the clinical significance of the findings. After the entire package
overall illicit drug use risk fell by 6.6 points on a scale whose maximum was 336, only 2.6 points greater than the decline in the control group.
Similarly for cannabis, on a scale reaching 39 the overall reduction was 3.1, just 1.4 greater than in the control group. Among patients whose
drug use have put them at risk of health problems, the impact of such small reductions on their future health is unclear. The
study excluded the highest risk patients most likely to be identified by doctors and of greatest concern, so could say nothing about how well
the recommended brief intervention plus referral procedure works among these priority patients.
As in some alcohol studies (1 2), a very minimal intervention, such as used in the current study, may have led to
as great a reduction in drug use/problems as the motivational-style interview.
The fact that patients usually saw the same person for intervention and follow-up assessment means not only could the assessors know
whether the patient had been in the brief intervention group (ie, they were not 'blinded' as recommended in such trials), but also that often
they were assessing the results of their own work. No biochemical tests were conducted to objectively test for substance use. This raises
the that both parties had the opportunity and the motivation to amplify the impacts of their interaction. Given the overall
small impact of the intervention, this could account for an appreciable part of its apparent effectiveness. In the USA about half the
participants were instead re-interviewed by a different person, perhaps one reason why their responses did not indicate extra risk reductions
from the intervention.
Some of the biggest effects were seen among opioid users in India, where nearly 10 points were sliced from opioid use severity scores (maximum 39) by the whole
package, over twice the decline in the control group. Half the patients targeted for their opioid use were daily or near daily users and all but a few were recruited in
India. Where, as in parts of that country, regular opioid use is normalised among socially included populations with family and work responsibilities, it seems that in
certain cultures it is susceptible to even quite brief intervention. It seems possible however that participants were motivated to deny continuing drug use (especially
in the case of brief intervention patients, to their counsellors), which compared to other countries they tended to see as contravening personal and family
responsibilities.
As the authors hint, screening of this kind will probably be reserved for medical and other settings likely to attract unusually many illegal drug
users. How willing they will be to own up to their use is unclear. In the validation studies for the ASSIST screening questionnaire, patients
were interviewed by researchers and assured of confidentiality, even in respect of their doctors – important to at least some of the patients.
In routine practice these doctors or their colleagues would be the ones asking the screening questions. Another departure from routine
practice was that the study largely relied on specially trained clinical research staff rather than the centres' usual staff, meaning the results
may not apply where clinical research staff are not available.
Assuming the results do translate to everyday practice, there remains the issue of which type of practice. Among the settings were sexually
transmitted disease clinics, a health centre associated with a drug treatment programme, a dental clinic primarily seeing poor patients in an
emergency, as well as primary health and community health clinics. At best pooling these results reveals the impact of the intervention at
settings with the characteristic they shared – being front-line medical services. At worst it jumbles apples with pears, perhaps one reason
why there was a highly significant variation in results from different countries.
Puzzling opposition in results from Australia and USA
British readers may be most interested in the somewhat opposing results from the two westernised developed nations in the study, Australia
and the USA. It should be stressed however that results from individual countries are subject to the idiosyncrasies of the study site,
population and procedures in that country, variations partly ironed out in the amalgamated results. Results from Australia were particularly
promising, but derived from STD clinics rather than generic primary care, and the unexplained variation between these two countries closest
to UK conditions makes it impossible to predict what the consequences might be of a similar study in the UK, especially in GP surgeries and
emergency departments, where brief intervention work is concentrated. Details below.
In Australia, three quarters of the largely young single population recruited at clinics for sexually transmitted diseases were identified as primarily having problems
with what seems to have been mainly stimulant use. Despite of all the nations averaging the highest risk score in relation to illegal drug use and the
shortest intervention (typically just eight minutes), this country also recorded the strongest intervention effects. Possibly this was a particularly health-conscious
population not representative of usual primary care patients in Britain.
The USA was the other westernised developed nation, and here results were at the opposite end of the scale – in the 'wrong' direction for illicit drugs in general and
for cannabis and stimulants, in each case nearly to a statistically significant degree. This could simply be chance variation but the consistency of the findings
suggests otherwise. If it did reflect a real and counterproductive effect, this pattern does not square with the intervention being overwhelmed by the consent
procedure or by the patients' previous experiences of treatment, influences which would have merely nullified the intervention. Adding to the puzzle is that
according to their own accounts at the follow-up interviews, the US patients' feelings about the brief intervention do not seem to explain why they failed to react to
by reducing their substance use risks. For example, almost 80% who received the brief intervention reported attempting to cut down as a result, similar to other
countries.
For more see the WHO ASSIST web site where you can download the research report on the featured evaluation, manuals for the screening tool and the brief
intervention, and the written self-help guide given to patients in the study.
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